Ibex Biosciences has a robust pipeline of unique pre-clinical programs consisting of Antibodies, Gene Therapies and Regeneration as summarized below:
Ibex currently has two pre-clinical therapeutic antibody programs for Oncology and Malaria, which are B411 and IBX13. We are also developing two other antibodies for treating inflammatory conditions with targeted in-vivo studies in the first quarter of 2023.
Ibex has developed a polyclonal for IHC diagnostics as well. Ibex plans to file a pre-IVD on this antibody by the end of the second half of 2022.
Ibex intends to conduct an in-vivo for Parkinson's Disease (BRLVV) in the 2nd half of 2022 using its regenerative platform it refers to as 'In-Situ Regeneration' or 'ISR' for short. This platform is similar to reprogramming but attempts to use gene therapy to facilitate a functional repair of damaged cells.
Ibex has a patent on the use of its Transcription factor for regeneration while inhibiting oncogenesis.
Ibex has two universal cancer Gene Therapies (F2 and P2) for direct targeting of cancer tumors. Ibex plans to enter an in-vivo study in the third quarter of 2022 for this program.
Ibex has developed two additional gene therapies for the treatment of non-oncological conditions, with a planned patent filing by the 1st quarter of 2023 for both.